Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age.
about
Identifying the start of multiple sclerosis injury: a serial DTI studyCharacterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.Conventional MRI in multiple sclerosis.Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report.Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.Brief report: "allergic symptoms" in children with Autism Spectrum Disorders. More than meets the eye?Perinatal stress, brain inflammation and risk of autism-review and proposal.Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosisSex-related factors in multiple sclerosis susceptibility and progression.A hematopoietic contribution to microhemorrhage formation during antiviral CD8 T cell-initiated blood-brain barrier disruption.Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups.Peptide derived from HIV-1 TAT protein destabilizes a monolayer of endothelial cells in an in vitro model of the blood-brain barrier and allows permeation of high molecular weight proteinsGuidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment.More immunotherapy for multiple sclerosis.Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.TGF-β regulation of encephalitogenic and regulatory T cells in multiple sclerosis.Finding a Balance between Protection and Pathology: The Dual Role of Perforin in Human Disease.Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis.Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study.Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells.Utility and Significance of Gadolinium-Based Contrast Enhancement in Posterior Reversible Encephalopathy Syndrome.Antibodies as predictors of complex autoimmune diseases and cancer.Hippocampal neurodegeneration in experimental autoimmune encephalomyelitis (EAE): potential role of inflammation activated myeloperoxidase.IFN-beta protects from vascular leakage via up-regulation of CD73.High numbers of perforin mRNA expressing CSF cells in multiple sclerosis patients with gadolinium-enhancing brain MRI lesions.A multicenter measurement of magnetization transfer ratio in normal white matter.Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats.Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis.EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis.A high-resolution three-dimensional T1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis.MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies.
P2860
Q28250952-B2E9B4AB-684E-4238-9831-689D688251E9Q30585635-71875522-64BB-4509-AF82-12393712E394Q31108855-7792C45B-A467-4B8E-9E7C-3B3562738BD1Q33700997-FA728EC9-9270-44A3-928E-C902FBB7E8F8Q34064209-16040493-81A5-4CF6-BE8F-A35B9EFCB01BQ34157800-C5DB37D3-76C1-4344-9740-B3C0B792935DQ34285045-F15E948C-D99A-46E3-8133-994CE4D9CB76Q34321561-67CBB253-785E-457F-9D5B-A7318A71F6AEQ35619427-0D96A349-32B8-41D5-9AAF-AB5C251BF069Q35953613-2F01CD44-10BC-48A0-A97A-0CBCC15BBF64Q36317642-558C1B12-D98B-407D-ADC3-A1321A062A61Q36492911-ED258C88-BE3E-4303-96CA-1066921730C5Q36792204-E885A961-CD98-48B1-A984-B9BFC21EF08BQ36839900-6C72CC6E-54F7-4A5E-ACC8-0CA2D3C3536FQ36896700-D9ADC77D-EA4F-440D-829E-AAD1EF1668BFQ37033692-E1EEFF5A-B947-4F48-B66C-227283571E61Q38375605-59717BD0-E3DD-4754-B1A0-65F714572B24Q39094862-BED52888-3926-45BE-8197-A41EC1612979Q40102071-334265C2-D7CA-482E-9A6D-70A911438CFBQ40190314-5ECAD774-1A0F-453E-A61D-DB708E9906EBQ40222496-07AF0DAF-95B2-4039-873D-C08F0DF208DBQ41139248-50A05057-1729-49D9-94BE-445F1A9B8CFFQ41616484-4A22C0AD-EB24-41F1-A640-8A23FA15E9A0Q44765537-1BBC06CB-10A0-410C-A91D-2A9B506A7D6AQ46081378-9FC075B9-2001-4921-A680-CCD695E6C49DQ46885617-00CB682A-C8F8-4568-BD75-E1DD189466A9Q48154911-BB07CFC9-ED71-4F0E-B498-EC9858B65827Q48243040-844E70A3-C8DA-47BC-B369-7566237ED0B7Q48465059-FCDCBB96-7904-4758-BE05-FD7BD7F1CD51Q48550799-F17027ED-768C-4CF2-AA7A-8100EF81D01DQ48565199-40C2B295-D954-413D-975F-D53EAAED52A5Q48841615-A170EB3A-1CE5-4FCF-B7AD-BAABC1DC8925Q48866045-48193CC7-2F5C-44F8-AE99-F5C403892CB2
P2860
Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Blood-brain barrier disruption ...... ip to course, gender, and age.
@en
Blood-brain barrier disruption ...... ip to course, gender, and age.
@nl
type
label
Blood-brain barrier disruption ...... ip to course, gender, and age.
@en
Blood-brain barrier disruption ...... ip to course, gender, and age.
@nl
prefLabel
Blood-brain barrier disruption ...... ip to course, gender, and age.
@en
Blood-brain barrier disruption ...... ip to course, gender, and age.
@nl
P2093
P921
P356
P1433
P1476
Blood-brain barrier disruption ...... ip to course, gender, and age.
@en
P2093
McFarland HF
P304
P356
10.1212/WNL.45.6.1122
P407
P577
1995-06-01T00:00:00Z